Lamellar Biomedical Raises £5.75M in Series C Funding

Lamellar Biomedical, a Scottish biotechnology company, raised £5.75 million in Series C funding. The round was led by Invesco Asset Management Limited and supported by the Scottish Investment Bank. The funds will be used to commercialize Lamelleye and Visco-ease, generate clinical data for Muco-ease, and expand the company's pipeline of pharmaceuticals.

Lamellar Biomedical Secures £5.75 Million Series C Funding for Expansion

Lamellar Biomedical is a Bellshill, Scotland, UK-based biotechnology company developing a range of patent-protected medical and pharmaceutical products. The company is developing a pipeline of novel patent-protected medical devices and pharmaceuticals targeting Dry Eye Disease (DED) with Lamelleye, Radiotherapy-Induced Xerostomia (RIX) with Visco-ease, and Cystic Fibrosis (CF) with Muco-ease. The pipeline products target conditions that are poorly served by current medications and therefore represent areas of high value unmet medical need.

Lamellar Biomedical is a biotechnology company developing a range of patent-protected medical and pharmaceutical products targeting Dry Eye Disease, Radiotherapy-Induced Xerostomia, and Cystic Fibrosis.

8 years ago

Lamellar Biomedical Secures £5.75 Million Series C Funding for Expansion

ProblemHealthcare

Solution

Covered on